OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to ...

Shai Biran; Investor Relations; Spero Therapeutics Inc. Esther Rajavelu; Interim President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Chief Business Officer; Spero ...

Are you pleasantly surprised?; Pam Bondi’s criminal investigation into something that isn’t criminal; just what everyone ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

The World Business Council for Sustainable Development (WBCSD), in collaboration with leading pharmaceutical companies and ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analy ...

President Trump’s vow to hit the global automotive industry with new duties risks raising inflation and inflaming trade-war ...

GSK is reportedly in late-stage negotiations ... Financial Times – comes just ahead of the annual JPMorgan healthcare conference, which starts next week, and generally sees a flurry of M&A ...

Last week's rumour that GSK was poised to make a bid to acquire ... The deal coincides with the start of the JP Morgan healthcare conference in San Francisco, which has become a popular venue ...

Good evening and welcome to Dyadic International's Year-End 2024 Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief ...

Full Year 2024 Conference Call & Audio Webcast BioVersys will host a conference call and webcast at 2:00 PM CET to discuss the financial results, provide an update on the company’s performance, ...